drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous gene-modified T cells expressing dual CARs targeting CD19 and CD22 to recognize and kill B-ALL blasts, aiming to reduce antigen escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express dual chimeric antigen receptors that bind CD19 and CD22 on B‑cell leukemia cells. CAR engagement activates the T cell, leading to cytokine release, proliferation, and targeted cytotoxic killing of CD19+/CD22+ blasts, with dual targeting designed to reduce antigen escape.
drug_name
CD19/CD22 CAR-T cells
nct_id_drug_ref
NCT06078306